Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399461 · ClinicalTrials.gov registry record
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 19
- Enrollment target
NCT03399461 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 19 participants.
The verdict
NCT03399461 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.
Interventions
- OTHER Sociodemographic questionnaire
- OTHER Patient Interview guide
- OTHER Caregiver interview guide
- OTHER Pediatric quality of life (PedsQL) questionnaire
- OTHER Clinical questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-09-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03399461
The ClinicalTrials.gov registry entry for NCT03399461 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sociodemographic questionnaire is the first listed.
NCT03399461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03399461 about?
NCT03399461 is a clinical study titled "Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)". WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. Th...
What is the current status of trial NCT03399461?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2018-01-24. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT03399461?
The interventions under investigation include: Sociodemographic questionnaire (OTHER), Patient Interview guide (OTHER), Caregiver interview guide (OTHER), Pediatric quality of life (PedsQL) questionnaire (OTHER), Clinical questionnaire (OTHER).
Who is sponsoring clinical trial NCT03399461?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.